FDA to Expand Medication-Assisted Treatment for Opioid Addiction

March 5, 2018

On Saturday, February 24, 2018, Health and Human Services (HHS) Secretary, Alex Azar announced that the FDA would be issuing guidance documents regarding expanded access to medication-assisted treatment (MAT) for opioid addiction.

What is Medication-Assisted Treatment?

The recent HHS announcement is part of FDA’s broader effort to encourage new treatments for opioid addiction.  MAT combines pharmacological treatment with substance abuse counseling and other behavioral supports.  Currently, there are three FDA-approved products for the treatment of opioid addiction, including:

  1. Buprenorphine
  2. Methadone
  3. Naltrexone

These drugs, which are used to reduce the cravings and withdrawal symptoms associated with opioid addiction, are intended to assist in the detox process.

Upcoming Guidance Documents

According to an article in the New York Times, the FDA plans to release two new related draft guidance documents in the coming weeks.  The first guidance will focus on improving the effectiveness of existing drugs.  More specifically, the FDA wants to “encourage the development of longer-acting formulations of existing drugs for opioid treatment.” The second guidance will focus on the development of new drugs that “don’t end addiction, but help with aspects of it, such as cravings, or overdoses, with the goal remaining complete abstinence.”  These two guidances will serve as recommendations for drug makers who are interested in developing a product for the treatment of opioid use disorder (OUD).

Lack of Access

In his announcement, Alex Azar noted that only one-third of specialty treatment programs in the United States utilize MAT.  One of the biggest problems with current treatment options is a lack of access for certain patients.  Many of these drugs require consistent administration, making it hard for many people, particularly those living in rural areas, to commit to a regular program.  A recently approved, once-monthly injectable version of buphrenorphine may be a promising indication of the future of OUD treatment.

Are you in the process of developing a drug for the treatment of OUD? Regardless of your product’s indication, we can help you obtain approval of any FDA-regulated product. Contact us today to learn more about our services and how we can help get your product through FDA as quickly and cost-effectively as possible.



Agency Alerts General Regulatory

October 5, 2016

FDA Redefines the Term “Healthy” in Food Labeling

On Wednesday, September 28th, the FDA issued a final guidance document regarding the inclusion of the term “healthy” on the labels of food products. The guidance, entitled “Use of the Term ‘Healthy’...

Read the Full Article
Agency Alerts General Regulatory

October 12, 2015

FDA Insider Shares Thoughts on Priority Review Vouchers

FDA’s priority review voucher program allows drug makers to receive expedited review of drug products intended to treat rare or neglected diseases (more details in our blog post here). The program...

Read the Full Article
Agency Alerts General Regulatory

December 1, 2015

FDA Extends Comment Period for Proposed Regulation of Intended Uses of Tobacco Products

On September 25, 2015, FDA published a notice of proposed rulemaking (NPRM) regarding the regulation of products made or derived from tobacco. In the Federal Register announcement, “FDA requested...

Read the Full Article